# Milestone Pharmaceuticals Inc. (MIST) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/MIST
## Company Profile
- Ticker: MIST
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Canada
- Tags: Cardio-Metabolic
## Stock Data
- Close: 1.125 USD
- Market cap: 164337333.6 USD
- Last updated: 2026-08-12
## Business Overview
### Self-Administered Cardiac Rescue Therapy
Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions that patients can administer outside a medical setting.
### CARDAMYST
CARDAMYST is an FDA-approved etripamil nasal spray that adults can self-administer to convert symptomatic paroxysmal supraventricular tachycardia to sinus rhythm.
### Atrial Fibrillation Expansion
The Phase 3 ReVeRA-301 study evaluates etripamil in atrial fibrillation with rapid ventricular rate. The program uses the same self-administered regimen approved for paroxysmal supraventricular tachycardia.
### International Development
The European Medicines Agency is reviewing etripamil for paroxysmal supraventricular tachycardia under the proposed brand TACHYMIST.
## Why The Stock Is Moving

Following the latest company update, “Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update”, MIST closed down 11.4% at $1.13 on Aug 12, 2026. The move occurred in the trading session associated with this earnings update.

## Future Catalysts

- Enrollment of the first patient in the Phase 3 ReVeRA-301 study of etripamil in atrial fibrillation with rapid ventricular rate.

## Recent News
- 2026-08-12 11:08 EST — [Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-announces-second-quarter-2026-financial-results-and-pr-8fdcd863) — Source: Milestone Pharmaceuticals Inc.
- 2026-08-04 20:01 EST — [Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026](https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-to-announce-second-quarter-2026-financial-results-on-a-bb22d826) — Source: Milestone Pharmaceuticals Inc.
- 2026-07-03 01:30 EST — [Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-56-74d5744c) — Source: Milestone Pharmaceuticals Inc.
- 2026-05-14 12:30 EST — [Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ](https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-to-present-at-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq) — Source: Milestone Pharmaceuticals Inc.
- 2026-05-13 11:11 EST — [Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-announces-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Milestone Pharmaceuticals Inc.